# Comparing ICH Q2(R2), FDA Bioanalytical Method Validation, and ISO 151025

## Quick Answer

- ICH Q2(R2) governs analytical method validation for pharmaceutical submissions, FDA bioanalytical method validation applies to nonclinical and clinical pharmacokinetic studies, and ISO 151025 addresses medical laboratory quality and competence requirements.
- Laboratories serving multiple regulatory domains must map each validation parameter to the applicable guideline because acceptance criteria and required performance characteristics differ across the three frameworks.
- No single guideline supersedes the others, and laboratories must confirm which regulation applies to their specific assay purpose before designing a validation plan.

## Understanding the Three Validation Frameworks

Laboratories operating under different regulatory jurisdictions face a practical problem when validating analytical methods. A method developed for pharmaceutical quality control may not satisfy the requirements for bioanalytical studies, and neither may meet the expectations of medical laboratory accreditation. The three documents most frequently cited in these discussions are ICH Q3(R2), FDA Bioanalytical Method Validation guidance, and ISO 15189. Each serves a distinct purpose, applies to different types of laboratories, and defines validation parameters with different levels of specificity.

ICH Q3(R2) is the International Council for Harmonisation guideline for validation of analytical procedures. It applies to analytical methods used in pharmaceutical development and quality control, including methods for drug substance and drug product testing. The guideline describes the performance characteristics that should be evaluated when validating a method, including accuracy, precision, specificity, detection limit, quantitation limit, linearity, and range. The current revision incorporates concepts from the ICH Q14 guideline on analytical procedure development and introduces a risk-based approach to method validation.

FDA bioanalytical method validation guidance applies to methods used to measure drug concentrations in biological matrices such as blood, plasma, serum, urine, and tissue. These methods support pharmacokinetic, bioavailability, and bioequivalence studies that are submitted to the FDA as part of drug development. The guidance emphasizes the need to validate methods for selectivity, accuracy, precision, recovery, calibration curve performance, and stability of the analyte in the biological matrix.

ISO 15189 is an international standard for medical laboratories that specifies requirements for quality and competence. It is broader than the other two frameworks because it covers the entire laboratory operation, including pre-examination, examination, and post-examination processes. Validation and verification of examination methods are part of the standard, but the standard does not prescribe specific acceptance criteria for analytical performance. Instead, it requires that laboratories establish and document the performance characteristics of their methods and verify that methods perform as expected in their own laboratory setting.

The practical consequence of these differences is that a laboratory cannot assume that a validation performed under one framework satisfies the requirements of another. A pharmaceutical quality control laboratory validating a method under ICH Q3(R2) may not need to evaluate the same parameters as a clinical laboratory validating a diagnostic assay under ISO 15189. Similarly, a contract research organization performing bioanalytical studies under FDA guidance must address matrix effects and stability that are not central to ICH Q3(R2) validation.

## Core Principles of Analytical Method Validation

Validation is the process of demonstrating that an analytical method is suitable for its intended purpose. The underlying principle is that a method must produce results that are reliable, reproducible, and appropriate for the decisions that will be made based on those results. This principle applies across all three guidelines, but the specific requirements differ.

### Accuracy and Trueness

Accuracy is the closeness of agreement between the measured value and the true value. In ICH Q3(R2), accuracy is expressed as the percentage recovery of a known amount of analyte added to the sample matrix. In FDA bioanalytical validation, accuracy is assessed by comparing the measured concentration to the nominal concentration of quality control samples. In ISO 15189, accuracy is addressed through the concept of trueness, which is the closeness of agreement between the average of an infinite number of replicate measurements and the true value.

The practical implication is that a laboratory must define how accuracy will be measured and what acceptance criteria will be applied. For a pharmaceutical method, accuracy is typically assessed across the range of the method using at least three concentration levels. For a bioanalytical method, accuracy is assessed using quality control samples at low, medium, and high concentrations relative to the calibration range. For a medical laboratory, accuracy may be assessed through participation in external quality assessment programs or through comparison with a reference method.

### Precision and Repeatability

Precision is the closeness of agreement between independent measurements obtained under specified conditions. ICH Q3(R2) distinguishes between repeatability, which is precision under the same operating conditions over a short time interval, and intermediate precision, which is precision within a laboratory on different days or with different analysts. Reproducibility, which is precision between laboratories, is also mentioned in ICH Q3(R2) but is not always required for every method.

FDA bioanalytical validation requires precision to be assessed at the same concentration levels as accuracy, using at least five replicates per level. The precision is expressed as the coefficient of variation, and the acceptance criteria are typically set at 15 percent for most concentrations and 20 percent at the lower limit of quantitation.

ISO 15189 does not specify numeric acceptance criteria for precision. Instead, the standard requires that the laboratory determine the precision of its methods and use that information to interpret patient results. The laboratory must document the precision of each method and ensure that the precision is acceptable for the clinical use of the method.

### Specificity and Selectivity

Specificity is the ability of a method to measure the analyte of interest without interference from other components in the sample. ICH Q3(R2) uses the term specificity, while FDA bioanalytical guidance uses the term selectivity. The concept is the same, but the application differs.

In a pharmaceutical method, specificity is demonstrated by showing that the method can measure the drug in the presence of excipients, degradation products, and other impurities. In a bioanalytical method, selectivity is demonstrated by showing that the method can measure the drug in the presence of endogenous matrix components, metabolites, and other drugs that may be present in the sample.

ISO 15189 requires that the laboratory verify that the method is appropriate for the intended clinical use. This includes an assessment of the method's specificity, but the standard does not prescribe a specific approach for demonstrating specificity.

### Linearity and Range

Linearity is the ability of a method to produce results that are directly proportional to the concentration of the analyte in the sample. ICH Q3(R2) requires that linearity be demonstrated across the range of the method, typically using at least five concentration levels. The range is the interval between the upper and lower concentration of the analyte that has been demonstrated to have acceptable accuracy, precision, and linearity.

FDA bioanalytical guidance requires a calibration curve for each analytical run. The curve must include at least six nonzero calibration standards, and the back-calculated concentrations of the standards must meet the acceptance criteria. The range of the method is defined by the lower limit of quantitation and the upper limit of quantitation.

ISO 15189 requires that the laboratory verify the linearity of its methods and document the reportable range. The standard does not prescribe a specific number of concentration levels, but the laboratory must demonstrate that the method is linear across the range that will be used for patient samples.

### Detection and Quantitation Limits

The detection limit is the lowest concentration of the analyte that can be detected but not necessarily quantified. The quantitation limit is the lowest concentration of the analyte that can be quantified with acceptable accuracy and precision. ICH Q3(R2) requires that both limits be established for methods that are used to measure low concentrations of the analyte.

FDA bioanalytical guidance requires that the lower limit of quantitation be established for each method. The lower limit of quantitation is the lowest concentration of the analyte that can be measured with acceptable accuracy and precision, and it must be at least five times the response of a blank sample.

ISO 15189 does not require the establishment of detection and quantitation limits for all methods. The standard requires that the laboratory verify the method's performance characteristics, including the limit of detection and the limit of quantitation, when these are relevant to the clinical use of the method.

## At a Glance

The following table summarizes the key differences between the three validation frameworks.

| Parameter | ICH Q3(R2) | FDA Bioanalytical Method Validation | ISO 15189 |
| --- | --- | --- | --- |
| Primary application | Pharmaceutical quality control | Clinical and nonclinical pharmacokinetic studies | Medical laboratory accreditation |
| Accuracy | Percentage recovery from spiked samples | Comparison to true concentration of quality control samples | Trueness assessed through external quality assessment or reference methods |
| Precision | Repeatability, intermediate precision, reproducibility | Coefficient of variation at multiple concentration levels | Precision documented and used for clinical interpretation |
| Selectivity | Specificity in the presence of impurities and excipients | Selectivity in the presence of matrix components | Verification of specificity for intended clinical use |
| Linearity | Demonstrated across the range with at least five levels | Calibration curve with at least six nonzero levels | Linearity established over the reportable range |
| Limits | Detection and quantitation limits established | Lower limit of quantitation established | Limits verified when relevant to clinical use |
| Acceptance criteria | Defined by the laboratory and justified | 15 percent for most concentrations, 20 percent at the lower limit of quantitation | Not prescribed by the standard, established by the laboratory |

## Practical Implementation of Validation Plans

A laboratory that operates under multiple regulatory frameworks must develop a validation plan that addresses the requirements of each applicable guideline. The plan should be written before the validation is performed and should include the following elements.

### Step 1: Define the Purpose of the Method

The first step is to define the purpose of the method. Is the method intended for pharmaceutical quality control, for bioanalytical studies, or for clinical diagnostic use? The answer to this question determines which guideline applies and which performance characteristics must be validated.

For a pharmaceutical quality control method, the validation plan should follow ICH Q3(R2). The plan should include the performance characteristics that are relevant to the method, such as accuracy, precision, specificity, linearity, and range. The plan should also include the acceptance criteria for each performance characteristic.

For a bioanalytical method, the validation plan should follow the FDA guidance. The plan should include the validation of accuracy, precision, selectivity, recovery, calibration curve performance, and stability. The plan should also include the acceptance criteria for each performance characteristic.

For a medical laboratory method, the validation plan should follow ISO 15189. The plan should include the verification of the method's performance characteristics, including accuracy, precision, and linearity. The plan should also include the documentation of the method's performance and the interpretation of the results.

### Step 2 and the Selection of the Validation Approach

The second step is to select the validation approach. The approach may be a full validation, a partial validation, or a cross-validation, depending on the purpose of the method and the extent of the changes to the method.

A full validation is performed when a new method is developed or when an existing method is changed significantly. A partial validation is performed when a method is changed in a way that does not affect all performance characteristics. A cross-validation is performed when two methods are used to measure the same analyte in the same study.

The selection of the validation approach should be documented in the validation plan. The plan should also include the number of runs, the number of replicates, and the concentration levels to be used in the validation.

### Step 3 and the Execution of the Validation

The third step is to execute the validation. The validation should be performed according to the validation plan, and the results should be recorded in a validation report.

The validation report should include the results of each performance characteristic, the acceptance criteria, and the conclusion as to whether the method meets the acceptance criteria. The report should also include any deviations from the validation plan and the impact of those deviations on the validation.

### Step 4 and the Documentation of the Validation

The fourth step is to document the validation. The documentation should include the validation plan, the validation report, and any supporting data. The documentation should be retained in the laboratory's quality system and should be available for review by regulatory authorities.

The documentation should also include the standard operating procedures for the method, the training records for the personnel who perform the method, and the records of the equipment used in the method.

## Records and Measurements

The records and measurements that are required for validation differ across the three frameworks. The following table summarizes the key records and measurements for each framework.

| Record or Measurement | ICH Q3(R2) | FDA Bioanalytical Method Validation | ISO 15189 |
| --- | --- | --- | --- |
| Validation plan | Required | Required | Required |
| Validation report | Required | Required | Required |
| Calibration curve data | Required for linearity | Required for each run | Required for the reportable range |
| Quality control data | Required for accuracy and precision | Required for each run | Required for the clinical use of the method |
| Stability data | Required for the method | Required for the analyte in the matrix | Required when relevant to the clinical use |
| Equipment records | Required | Required | Required |
| Personnel training records | Required | Required | Required |

## Common Failure Patterns

Laboratories that attempt to use a single validation approach for all three frameworks often encounter common failure patterns. These failures can be avoided by understanding the differences between the frameworks and by designing a validation plan that addresses the requirements of each applicable guideline.

### Failure to Establish the Lower Limit of Quantitation

One common failure is the failure to establish the lower limit of quantitation for a bioanalytical method. The lower limit of quantitation is the lowest concentration of the analyte that can be measured with acceptable accuracy and precision. The FDA guidance requires that the lower limit of quantitation be established for each method, and the acceptance criteria for the lower limit of quantitation are typically 20 percent for accuracy and precision.

A laboratory that does not establish the lower limit of quantitation may not be able to measure the analyte at the concentrations that are relevant to the study. This can lead to the rejection of the study data and the need to repeat the study.

### Failure to Assess Stability

Another common failure is the failure to assess the stability of the analyte in the biological matrix. The FDA guidance requires that the stability of the analyte be assessed under the conditions that the samples will be stored and processed. This includes the stability of the analyte in the matrix, the stability of the analyte in the processed samples, and the stability of the analyte through freeze-thaw cycles.

A laboratory that does not assess the stability of the analyte may not be able to ensure that the measured concentration reflects the concentration of the analyte at the time of the sample collection. The laboratory may also not be able to ensure that the analyte is stable during the storage and processing of the samples.

### Failure to Verify the Method for the Intended Use

A laboratory that uses a method for a clinical purpose without verifying the method for that purpose may fail to meet the requirements of ISO 15189. The standard requires that the laboratory verify the method for the intended use, which includes an assessment of the method's accuracy, precision, and linearity.

A laboratory that does not verify the method for the intended use may not be able to ensure that the method is suitable for the clinical use of the method. The laboratory may also not be able to ensure that the results are reliable and reproducible.

### Failure to Document the Validation

A laboratory that fails to document the validation may not be able to demonstrate that the method is suitable for its intended purpose. The documentation should include the validation plan, the validation report, and the data that support the validation.

A laboratory that does not document the validation may not be able to provide the evidence that the method is valid when the laboratory is audited by a regulatory authority. The laboratory may also not be able to demonstrate that the method is suitable for the intended use of the method.

## Welfare and Safety Context

The validation of analytical methods is not directly related to animal welfare, but the laboratory that performs the validation must follow the biosafety principles that are described in the Biosafety in Microbiological and Biomedical Laboratories (BMBL) guidelines. The BMBL guidelines describe the principles of biosafety, including risk assessment, containment, and institutional oversight.

The laboratory must assess the risk of the work that is performed and must implement the appropriate containment measures. The laboratory must also follow the institutional oversight requirements that are described in the BMBL guidelines.

The laboratory that works with recombinant or synthetic nucleic acid molecules must follow the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. The NIH guidelines describe the oversight requirements for the work and the containment measures that must be implemented.

The laboratory must also follow the standard of practice for the molecular biology methods that are used in the laboratory. The National Library of Medicine provides a gateway to the authoritative laboratory-method and molecular-biology references that can be used to support the laboratory's work.

## Limitations of the Guidelines

Each of the three guidelines has limitations that the laboratory must understand.

### ICH Q3(R2) Limitations

ICH Q3(R2) is designed for pharmaceutical quality control methods. The guideline does not address the validation of methods that are used for the measurement of the drug in biological matrices. The guideline also does not address the stability of the analyte in the biological matrix.

### FDA Bioanalytical Method Validation Limitations

The FDA guidance is designed for bioanalytical methods that are used in clinical and nonclinical studies. The guidance does not address the validation of methods for pharmaceutical quality control. The guidance also does not address the clinical interpretation of the results.

### ISO 15189 Limitations

ISO 15189 is designed for medical laboratories. The standard does not prescribe the acceptance criteria for the performance characteristics of the method. The standard also does not address the validation of methods for pharmaceutical quality control or for bioanalytical studies.

## Professional Escalation Criteria

The laboratory should escalate the issue to the appropriate professional when the laboratory cannot resolve the issue. The escalation criteria include the following.

The laboratory should escalate the issue when the method does not meet the acceptance criteria for the performance characteristics. The laboratory should also escalate the issue when the method is not suitable for the intended use of the method.

The laboratory should escalate the issue when the laboratory cannot determine the cause of the failure. The laboratory should also escalate the issue when the laboratory cannot resolve the issue with the resources that are available.

The laboratory should escalate the issue to the quality assurance manager, the laboratory director, or the regulatory affairs specialist. The laboratory should also escalate the issue to the manufacturer of the equipment or the reagent when the issue is related to the equipment or the reagent.

## Building a Cross-Guideline Validation Matrix for Multi-Regime Laboratories

Laboratories that serve pharmaceutical, bioanalytical, and medical diagnostic clients face a recurring operational problem. A single method may need to satisfy ICH Q2(R2) for one submission, FDA bioanalytical method validation expectations for another, and ISO 15189 requirements for a third. The practical difficulty is not understanding each guideline in isolation but managing the overlaps, gaps, and conflicting acceptance criteria when one method serves multiple purposes. A decision matrix that maps each validation parameter to the governing guideline, the required evidence, and the acceptance threshold provides a workable solution.

### Constructing the Validation Parameter Matrix

The first step in building a cross-guideline validation matrix is to list every validation parameter that appears in any of the three frameworks. The master list should include accuracy, precision, specificity or selectivity, linearity, range, detection limit, quantitation limit, recovery, matrix effects, stability, carryover, dilution integrity, and robustness. Each parameter is then assigned a row in the matrix, and each guideline is assigned a column. The laboratory fills in the cell with the specific requirement from that guideline, the evidence that must be collected, and the acceptance criterion that will be applied.

The matrix serves a practical purpose beyond documentation. When a laboratory plans a validation study, the matrix becomes the checklist for the validation protocol. When a laboratory audits its own work, the matrix becomes the basis for the gap analysis. When a laboratory responds to a regulatory finding, the matrix shows which guideline was applied and why.

A laboratory that serves pharmaceutical quality control and clinical research should build the matrix with three columns, one for each guideline. The laboratory that serves only one regulatory domain can still benefit from the matrix because it shows where the other guidelines would impose additional requirements if the method is later used for a different purpose.

### Parameter Mapping and Evidence Requirements

The first parameter to map is accuracy. ICH Q 40(R2) requires accuracy to be demonstrated across the range of the method using at least three concentration levels, with the results expressed as the percentage recovery of the known amount of analyte added to the sample matrix. FDA bioanalytical method validation requires accuracy to be assessed by comparing the measured concentration to the nominal concentration of quality control samples at low, medium, and high concentrations relative to the calibration range. ISO 15189 addresses accuracy through the concept of trueness, which is the closeness of agreement between the average of replicate measurements and the true value, and the laboratory must establish how trueness will be assessed, typically through external quality assessment or comparison with a reference method.

The evidence gap appears when a laboratory validates a method under one guideline and then uses the method under another. A method validated under ICH Q 40(R2) with spiked sample recovery data may not have the quality control sample data that FDA expects. A method validated under FDA guidance with quality control data may not have the external quality assessment participation that ISO 15189 requires. The matrix makes this gap visible before the laboratory submits data to a regulator.

The second parameter to map is precision. ICH Q 40(R2) distinguishes repeatability, intermediate precision, and reproducibility. FDA bioanalytical method validation requires precision to be assessed at the same concentration levels as accuracy, using at least five replicates per level, with the coefficient of variation typically set at 15 percent for most concentrations and 20 percent at the lower limit of quantitation. ISO 15189 does not prescribe numeric acceptance criteria for precision but requires the laboratory to determine the precision of its methods and use that information to interpret patient results.

The matrix should record the precision data that already exists and the data that must be collected for each guideline. A laboratory that has repeatability data from an ICH validation may not have the five replicates per level that FDA expects. A laboratory that has FDA precision data may not have the long-term precision data that ISO 15189 uses for clinical interpretation.

The third parameter to map is specificity and selectivity. ICH Q 40(R2) uses the term specificity and requires the method to measure the analyte in the presence of excipients, degradation products, and impurities. FDA bioanalytical method validation uses the term selectivity and requires the method to measure the analyte in the presence of endogenous matrix components, metabolites, and other drugs. ISO 15189 requires the laboratory to verify that the method is appropriate for the intended clinical use, including an assessment of specificity.

The matrix should record the interference studies that have been performed and the matrices that have been tested. A pharmaceutical method that has been tested with excipients may not have been tested with hemolyzed, lipemic, or icteric samples that are relevant to a clinical laboratory. A bioanalytical method that has been tested with plasma may not have been tested with the sample types that a clinical laboratory receives.

### Acceptance Criteria Reconciliation

The most difficult part of the matrix is reconciling the acceptance criteria across the three guidelines. ICH Q 40(R2) does not prescribe specific numeric acceptance criteria for most parameters. The guideline requires the laboratory to define the acceptance criteria and justify them based on the intended use of the method. FDA bioanalytical method validation provides specific numeric criteria for accuracy and precision, with 15 percent for most concentrations and 20 percent at the lower limit of quantitation. ISO 15189 does not prescribe numeric acceptance criteria at all, leaving the laboratory to establish criteria that are appropriate for the clinical use of the method.

The laboratory must decide which acceptance criteria to apply when the same method is used for multiple purposes. The conservative approach is to apply the most stringent criterion from any of the applicable guidelines. The risk-based approach is to apply the criterion that is appropriate for the specific use of the method at the time of the validation.

The matrix should record the acceptance criteria that were applied and the justification for each criterion. The laboratory should also record the actual performance data for each parameter so that the data can be compared to the criteria from each guideline. This comparison is the basis for the gap analysis that the laboratory performs before submitting data to a second regulatory domain.

### The Matrix as a Gap Analysis Tool

The matrix becomes a gap analysis tool when the laboratory uses it to compare the evidence that exists with the evidence that is required. The laboratory should perform the gap analysis at the start of a new validation study and again before the method is used for a new purpose.

The gap analysis starts with the matrix listing all parameters and the evidence required for each guideline. The laboratory then marks the evidence that already exists from prior validation studies. The remaining cells are the gaps that must be filled.

The gap analysis should also include the stability data. FDA bioanalytical method validation requires the assessment of the stability of the analyte in the biological matrix, the stability of the processed samples, and the stability through freeze-thaw cycles. ICH Q 40(R2) requires stability data for the method but does not require the same matrix stability studies. ISO 15189 requires stability data when the stability is relevant to the clinical use of the method.

The matrix should record the stability conditions that have been tested, the storage temperatures, the storage durations, and the acceptance criteria. The gap analysis shows whether the stability data from one guideline covers the requirements of the other guidelines.

### The Matrix in Practice

The following example shows how the matrix works in practice. A laboratory has a liquid chromatography method for the measurement of a drug in human plasma. The method was validated under FDA bioanalytical method validation for a pharmacokinetic study. The laboratory now wants to use the same method for a clinical diagnostic test that will be accredited under ISO 15189.

The matrix shows that the FDA validation includes accuracy, precision, selectivity, recovery, calibration curve performance, and stability. The matrix also shows that the FDA validation does not include the verification of the method for the clinical use, the assessment of the reportable range, or the participation in external quality assessment that ISO 15189 requires.

The gap analysis shows that the laboratory must perform additional work before the method can be used for the clinical purpose. The laboratory must verify the method for the clinical use, establish the reportable range, and participate in an external quality assessment program. The matrix also shows that the laboratory must document the precision of the method for the clinical interpretation of the results.

The matrix is also useful for the reverse situation. A laboratory has a method that was validated under ISO 15189 for a clinical diagnostic. The laboratory now wants to use the method for a bioanalytical study that will be submitted to the FDA. The matrix shows that the ISO validation does not include the lower limit of quantitation, the calibration curve performance, or the stability of the analyte in the biological matrix that the FDA guidance requires. The laboratory must perform additional validation before the method can be used for the bioanalytical study.

### Common Failure Patterns in Cross-Guideline Validation

The most common failure pattern is the assumption that a validation performed under one guideline satisfies the requirements of another guideline. This assumption leads to the submission of incomplete data and the rejection of the validation by the second regulatory authority.

The second common failure pattern is the use of the wrong acceptance criteria. A laboratory that uses the ICH Q 40(R2) acceptance criteria for a bioanalytical method may not meet the FDA requirements for the lower limit of quantitation. A laboratory that uses the FDA acceptance criteria for a clinical method may not meet the ISO 15189 requirements for the clinical interpretation of the results.

The third common failure pattern is the failure to document the validation evidence in a way that is accessible to the regulatory authority. The laboratory must be able to show the evidence for each parameter in the matrix and the acceptance criteria that were applied. The laboratory must also be able to show the justification for the choice of the acceptance criteria.

The fourth common failure pattern is the failure to update the matrix when the method is changed. A change to the method, such as a change in the sample preparation or the chromatographic conditions, may require a partial validation. The matrix must be updated to reflect the change and the new evidence that is required.

### Records and Measurements for the Matrix

The matrix is a living document that must be maintained in the laboratory quality system. The matrix should be reviewed and updated at least annually and whenever the method is changed or the regulatory requirements are updated.

The matrix should be accompanied by the validation plan, the validation report, and the raw data that support the validation. The raw data should include the calibration curve data, the quality control data, the stability data, and the interference data. The raw data should be retained in the laboratory quality system and should be available for review by the regulatory authorities.

The matrix should also be accompanied by the standard operating procedures for the method, the training records for the personnel who perform the method, and the equipment records. The matrix should be referenced in the standard operating procedures so that the laboratory personnel know which guideline applies to the method and which acceptance criteria are used.

### Professional Escalation Criteria

The laboratory should escalate the issue to the appropriate professional when the matrix reveals a gap that cannot be filled with the available resources. The laboratory should escalate the issue when the method does not meet the acceptance criteria for a parameter that is required by a guideline. The laboratory should escalate the issue when the laboratory cannot determine the cause of the failure or when the laboratory cannot resolve the issue with the available resources.

The laboratory should escalate the issue to the quality assurance manager, the laboratory director, or the regulatory affairs specialist. The laboratory should also escalate the issue to the manufacturer of the equipment or the reagent when the issue is related to the equipment or the reagent.

The laboratory should also escalate the issue when the matrix shows that the method is not suitable for the intended use of the method. The laboratory should not use the method for a purpose that is not supported by the validation evidence.

### The Matrix and the Laboratory Quality System

The matrix is a practical tool that supports the laboratory quality system. The matrix is not a substitute for the validation plan or the validation report, but it is a tool that helps the laboratory to plan the validation, execute the validation, and document the validation.

The matrix is also a tool that helps the laboratory to communicate with the regulatory authorities. The matrix shows the regulatory authority that the laboratory has considered the requirements of each guideline and has applied the appropriate acceptance criteria. The matrix shows the regulatory authority that the laboratory has identified the gaps and has filled the gaps with the additional validation evidence.

The matrix is also a tool that helps the laboratory to train the new personnel. The matrix shows the new personnel the requirements of each guideline and the evidence that is required for each parameter. The matrix is a training tool that helps the new personnel to understand the validation process and the regulatory requirements.

### The Matrix and the Biosafety Context

The validation matrix does not directly address biosafety, but the laboratory that performs the validation must follow the biosafety principles that are described in the Biosafety in Microbiological and Biomedical Laboratories (BMBL) guidelines. The BMBL guidelines describe the principles of biosafety, including risk assessment, containment, and institutional oversight. The laboratory must assess the risk of the work that is performed and must implement the appropriate containment measures. The laboratory must also follow the institutional oversight requirements that are described in the BMBL guidelines.

The laboratory that works with recombinant or synthetic nucleic acid molecules must follow the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. The NIH guidelines describe the oversight requirements for the work and the containment measures that must be implemented. The laboratory must also follow the standard of practice for the molecular biology methods that are used in the laboratory. The National Library of Medicine provides a gateway to the authoritative laboratory-method and molecular-biology references that can be used to support the laboratory's work.

The laboratory that uses quantitative PCR methods should follow the MIQE guidelines for the reporting of the qPCR data. The MIQE guidelines describe the minimum information that should be reported for the qPCR experiments, including the controls, the transparency, and the interpretation of the results. The MIQE guidelines are relevant to the validation of the qPCR methods that are used in the laboratory.

The laboratory that uses measurement standards should follow the NIST laboratory programs. The NIST laboratory programs describe the measurement science, the standards, the calibration, and the quality context for the laboratory. The NIST laboratory programs are relevant to the laboratory that uses the measurement standards for the calibration of the equipment and the validation of the methods.

### The Matrix as a Decision Framework

The matrix is a decision framework that the laboratory uses to determine which validation parameters are required for each method and which acceptance criteria are applied. The matrix is a practical tool that the laboratory uses to plan the validation, execute the validation, and document the validation. The matrix is also a tool that the laboratory uses to communicate with the regulatory authorities and to train the new personnel.

The matrix is not a static document. The matrix must be updated whenever the method is changed, whenever the regulatory purpose is changed, and whenever the guideline is updated. The matrix must be maintained in the laboratory quality system and must be available for review by the regulatory authorities.

The matrix is a tool that the laboratory uses to ensure that the method is suitable for the intended purpose. The matrix is a tool that the laboratory uses to ensure that the validation evidence is complete and that the acceptance criteria are appropriate. The matrix is a tool that the laboratory uses to ensure that the laboratory is in compliance with the applicable guidelines.

The matrix is a practical decision framework that the laboratory can use to manage the validation of the methods across the three regulatory domains. The matrix is a tool that the laboratory can use to identify the gaps in the validation evidence and to fill the gaps with the additional validation studies. The matrix is a tool that the laboratory can use to ensure that the method is suitable for the intended purpose and that the laboratory is in compliance with the applicable guidelines.

## Frequently Asked Questions

### What is the difference between ICH Q3(R2) and FDA bioanalytical method validation?

ICH Q3(R2) is the international guidance for the validation of analytical procedures for pharmaceutical quality control. FDA bioanalytical method validation is the guidance for the validation of methods used to quantify the analyte in biological matrices for clinical and nonclinical studies. The two guidelines differ in the performance characteristics that are required and the acceptance criteria that are applied.

### What is the difference between ICH Q3(R2) and ISO 15189?

ICH Q3(R2) is the international guidance for the validation of analytical procedures for pharmaceutical quality control. ISO 15189 is the international standard for medical laboratory accreditation. The two guidelines differ in the scope of the requirements and the acceptance criteria that are applied.

### What is the difference between FDA bioanalytical method validation and ISO 15189?

FDA bioanalytical method validation is the guidance for the validation of analytical methods for the quantification of the analyte in biological fluids. ISO 15189 is the standard for medical laboratory accreditation. The two guidelines differ in the scope of the validation and the acceptance criteria that are applied.

### Which guideline should a laboratory follow?

The laboratory should follow the guideline that applies to the purpose of the method. The laboratory should follow ICH Q3(R2) for pharmaceutical quality control, FDA bioanalytical method validation for clinical and nonclinical studies, and ISO 15189 for medical laboratory accreditation.

### What is the lower limit of quantitation?

The lower limit of quantitation is the lowest concentration of the analyte that can be measured with acceptable accuracy and precision. The lower limit of quantitation is established for bioanalytical methods and is the lowest concentration of the calibration curve.

### What is the difference between accuracy and precision?

Accuracy is the closeness of agreement between the measured value and the true value. Precision is the closeness of agreement between independent measurements of the same sample. A method can be precise but not accurate, and a method can be accurate but not precise.

### What is the difference between specificity and selectivity?

Specificity is the ability of a method to measure the analyte of interest in the presence of other components. Selectivity is the ability of a method to measure the analyte of interest in the presence of other components that may be present in the sample. The two terms are often used interchangeably, but they have different meanings in the context of the validation.

### What is the difference between a full validation and a partial validation?

A full validation is performed when a method is introduced or when a method is changed significantly. A partial validation is performed when a method is changed in a way that does not affect all of the performance characteristics. The extent of the validation depends on the nature of the change to the method.

## Related Diagnostic Guides

- [Method Validation in Clinical Laboratories: A Practical Protocol](/knowledge/diagnostics/emerging-tech/method-validation-in-clinical-laboratories-a-practical-protocol)
- [Biosafety Regulations and Guidelines: A Global Overview for Diagnostic Laboratories](/knowledge/diagnostics/emerging-tech/biosafety-regulations-and-guidelines-a-global-overview-for-diagnostic-laboratories)
- [Biological Waste Management in Diagnostic Laboratories: A Practical Guide](/knowledge/diagnostics/emerging-tech/biological-waste-management-in-diagnostic-laboratories-a-practical-guide)
- [Biosafety Levels 1-4: A Decision Framework for Diagnostic Laboratories](/knowledge/diagnostics/emerging-tech/biosafety-levels-1-4-a-decision-framework-for-diagnostic-laboratories)
- [Biosafety Manual Development: A Template for Diagnostic Laboratories](/knowledge/diagnostics/emerging-tech/biosafety-manual-development-a-template-for-diagnostic-laboratories)

## References and Further Reading

- [Molecular Biology and Laboratory Methods](https://www.ncbi.nlm.nih.gov/books). National Library of Medicine.
- [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html). CDC and NIH.
- [NIH Guidelines for Recombinant or Synthetic Nucleic Acid Molecules](https://osp.od.nih.gov/policies/biosafety-and-biosecurity-policy/nih-guidelines-for-research-involving-recombinant-or-synthetic-nucleic-acid-molecules). National Institutes of Health.
- [Addgene Protocols](https://www.addgene.org/protocols). Addgene.
- [MIQE Guidelines](https://academic.oup.com/clinchem/article/55/4/611/5631762). Clinical Chemistry.
- [NIST Laboratory Programs](https://www.nist.gov/laboratories). National Institute of Standards and Technology.
- [Laboratory Biosafety Manual](https://www.who.int/publications/i/item/9789240011311). World Health Organization.
- [NCBI Literature Resources](https://www.ncbi.nlm.nih.gov/). National Center for Biotechnology Information.
- [3D printed system using &lt,i&gt,ex vivo&lt,/i&gt, porcine eye globes to investigate intracorneal absorption of dexpanthenol from contact lens care solution and eye drops.](https://doi.org/10.1016/j.ijpx.2025.100472). 2026.
- [Quality-by-design based RP-HPLC analytical method for the estimation of quercetin in silver-metal organic frameworks (AgMOF): a Box-Behnken optimization approach.](https://doi.org/10.1038/s41598-025-32452-6). 2025.
- [Development and validation of a sustainable UHPLC method for quantification and impurity profiling of carfilzomib.](https://doi.org/10.1038/s41598-025-33731-y). 2025.

> This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.